Wegovy vs. Mounjaro: A Clinical Comparison of Efficacy, Safety, and Cost

Among the most common questions patients and clinicians face in obesity pharmacotherapy today is: Which is better — Wegovy (semaglutide) or Mounjaro/Zepbound (tirzepatide)? Both medications belong to the GLP-1 receptor agonist class, both are administered as once-weekly subcutaneous injections, and both produce clinically meaningful weight loss far superior to lifestyle intervention alone. However, there are important differences in mechanism, efficacy, side effect profile, cost, and insurance coverage that make a structured comparison essential for informed treatment decision-making.

Mechanism of Action: GLP-1 Alone vs. GLP-1 Plus GIP

The most fundamental difference between the two medications is their receptor target profile:

• Semaglutide (Wegovy): A selective GLP-1 receptor agonist. It binds and activates GLP-1 receptors throughout the body — in the pancreas, brain, gastrointestinal tract, and cardiovascular system — with high potency and prolonged duration of action due to its albumin-binding fatty acid modification.
• Tirzepatide (Mounjaro/Zepbound): A dual GIP/GLP-1 receptor agonist (sometimes called a "twincretin"). It is a synthetic peptide engineered to activate both the GIP receptor (with native GIP-like potency) and the GLP-1 receptor. The GIP receptor co-activation appears to synergize with GLP-1 receptor signaling to produce greater adipose tissue fat mobilization, enhanced insulin sensitivity, and potentially reduced gastrointestinal side effects.

The additional GIP receptor agonism is the pharmacological basis for tirzepatide’s superior weight loss outcomes and is what distinguishes it from the GLP-1 RA class proper — though it is frequently discussed in the same clinical context.

Head-to-Head Efficacy: SURMOUNT-5 Results

For years, clinicians compared semaglutide and tirzepatide only indirectly across separate trial programs. The SURMOUNT-5 trial provided the first direct head-to-head randomized comparison in adults with obesity or overweight without diabetes. Key results:

• Tirzepatide 15 mg: mean weight loss of approximately 20.2% at 72 weeks
• Semaglutide 2.4 mg: mean weight loss of approximately 13.7% at 72 weeks
• Difference: tirzepatide produced approximately 47% greater relative weight loss compared to semaglutide
• Patients achieving ≥25% weight loss: approximately 32% on tirzepatide vs. 16% on semaglutide

These results establish tirzepatide as the more efficacious agent for weight loss based on current evidence. However, both medications produce clinically meaningful weight loss far superior to placebo, and semaglutide may be a preferred option in specific clinical contexts.

💡 💡 Clinical Pearl

When interpreting head-to-head trial data, note that average results mask substantial individual variation. Approximately 30–40% of patients are "high responders" on either medication, achieving weight loss well above the trial mean, while a smaller proportion are minimal responders. Clinical practice increasingly suggests that if a patient has not achieved ≥5% weight loss after 12–16 weeks at a therapeutic dose, a medication switch or augmentation strategy should be discussed — rather than continuing an ineffective regimen indefinitely.

Comparative Weight Loss Milestones

The following summary compares key efficacy endpoints across the pivotal trials:

• Mean weight loss at maximum dose: Semaglutide 2.4 mg → ~14.9% (STEP 1); Tirzepatide 15 mg → ~20.9% (SURMOUNT-1)
• ≥15% weight loss achieved: ~50% of patients on semaglutide; ~63% on tirzepatide 15 mg
• ≥20% weight loss achieved: ~32% on semaglutide; ~57% on tirzepatide 15 mg
• HbA1c reduction in T2D: Tirzepatide demonstrated superior glycemic control, reducing HbA1c by up to 2.58% vs. semaglutide’s ~1.8% reduction in comparable populations

Safety and Tolerability Comparison

Both medications share the same general adverse effect profile dominated by gastrointestinal symptoms. Key differences include:

• Nausea: Approximately 44% with semaglutide 2.4 mg vs. ~31% with tirzepatide 15 mg. The lower nausea rate with tirzepatide may reflect GIP receptor co-activation modulating gastrointestinal motility.
• Vomiting: ~24% semaglutide vs. ~13% tirzepatide
• Serious adverse events: Comparable rates in trials; both carry the same boxed warning for thyroid C-cell tumor risk and the same contraindications (personal/family history of medullary thyroid carcinoma or MEN 2)
• Gallbladder disease: Seen with both agents, likely due to rapid weight loss rather than a direct drug effect. Both prescribing information documents note this risk.
• Pancreatitis: Rare with both medications; caution warranted in patients with prior pancreatitis history

Cardiovascular Evidence Comparison

Semaglutide currently has a stronger cardiovascular outcomes evidence base for weight management specifically. The SELECT trial (2023) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% in adults with pre-existing cardiovascular disease and obesity, leading to an expanded FDA indication. Cardiovascular outcome trial data for tirzepatide in obesity (the SURMOUNT-MMO trial) is ongoing and has not yet produced published results.

For patients with established cardiovascular disease, semaglutide’s cardiovascular mortality benefit may be an important differentiating factor in treatment selection.

Cost and Access Considerations

Cost is a major barrier to GLP-1 RA access in many healthcare systems:

• List price (USA): Both Wegovy and Zepbound carry list prices in the range of $1,000–$1,400 per month without insurance. Actual out-of-pocket cost depends heavily on insurance coverage, prior authorization, and manufacturer savings programs.
• Insurance coverage: Coverage varies widely. Many commercial insurance plans cover these medications with prior authorization. Medicare Part D coverage for weight management drugs has historically been limited but is evolving. Medicaid coverage varies by state.
• Manufacturer savings programs: Both Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) offer savings card programs for commercially insured patients, potentially reducing out-of-pocket costs significantly.

How to Choose Between the Two

Clinical decision-making should account for the following factors:

• Degree of weight loss needed: If the patient’s treatment goals require ≥20% weight loss or they wish to maximize weight loss before considering surgery, tirzepatide’s superior efficacy makes it the preferred first-line choice.
• Cardiovascular disease: Patients with established CVD and obesity may benefit from semaglutide’s proven MACE reduction (SELECT trial data).
• Tolerability: Patients with significant nausea on semaglutide may tolerate tirzepatide better, and vice versa.
• Cost and coverage: Insurance coverage for one agent but not the other may be the decisive practical factor for many patients.
• Type 2 diabetes: Both agents reduce HbA1c; tirzepatide generally produces greater glycemic improvement.

For more background on how these medications work, see What Are GLP-1 Receptor Agonists?

💡 Frequently Asked Questions (FAQ)

Q1: Should I switch from Wegovy to Mounjaro if I’m not losing enough weight?
A1: If you’ve been on the maximum tolerated dose of semaglutide for at least 12–16 weeks and have achieved less than 5% weight loss, a switch to tirzepatide is a reasonable clinical consideration. Discuss this with your prescribing physician, who will also assess tolerability, insurance coverage, and other individual factors before recommending a change.

Q2: Can I take both semaglutide and tirzepatide together?
A2: No. Combining two GLP-1 receptor agonists (including a dual GIP/GLP-1 agonist) is not medically indicated, not studied for safety or efficacy, and not recommended. Only one agent from this class should be used at a time.

Q3: Which medication has better long-term safety data?
A3: Semaglutide has a longer market history and more accumulated real-world evidence, including the landmark SELECT cardiovascular outcomes trial. Tirzepatide is newer but has substantial Phase 3 data across the SURMOUNT and SURPASS programs. Both have favorable safety profiles in the published trial literature, but long-term post-marketing safety data for tirzepatide continues to accumulate.

📚 References & Sources

1. Wilding, J.P.H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002.
2. Jastreboff, A.M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216.
3. American Diabetes Association. (2024). Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes. Diabetes Care, 47(Suppl.1).